4.7 Review

Chitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines

期刊

VACCINES
卷 10, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/vaccines10111906

关键词

chitosan; chitosan-based nanoparticles; vaccine adjuvant; delivery system

资金

  1. Pioneer and Leading Goose R&D Programs of Zhejiang [2022C02031]
  2. Natural Science Foundation of Heilongjiang Province [LH2020H129]
  3. Natural Science Foundation of Zhejiang Province [LTY22E030002]
  4. Taizhou Science and Technology Plan Project [22nya04]

向作者/读者索取更多资源

This article introduces the application of chitosan in vaccine adjuvants and drug delivery systems. Chitosan has good biocompatibility and low toxicity, and can effectively enhance immune responses. Chitosan-based nanoparticles serve as excellent delivery systems and play important roles in protein vaccines and nucleic acid vaccines.
With the support of modern biotechnology, vaccine technology continues to iterate. The safety and efficacy of vaccines are some of the most important areas of development in the field. As a natural substance, chitosan is widely used in numerous fields-such as immune stimulation, drug delivery, wound healing, and antibacterial procedures-due to its good biocompatibility, low toxicity, biodegradability, and adhesion. Chitosan-based nanoparticles (NPs) have attracted extensive attention with respect to vaccine adjuvants and delivery systems due to their excellent properties, which can effectively enhance immune responses. Here, we list the classifications and mechanisms of action of vaccine adjuvants. At the same time, the preparation methods of chitosan, its NPs, and their mechanism of action in the delivery system are introduced. The extensive applications of chitosan and its NPs in protein vaccines and nucleic acid vaccines are also introduced. This paper reviewed the latest research progress of chitosan-based NPs in vaccine adjuvant and drug delivery systems.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据